Reuters logo
BRIEF-Indivior ‍says FDA to review New Drug Application for RBP-6000​
October 3, 2017 / 3:15 PM / 2 months ago

BRIEF-Indivior ‍says FDA to review New Drug Application for RBP-6000​

Oct 3 (Reuters) - Indivior Plc -

* ‍FDA posts Federal Register notice for an advisory committee meeting to review​

* Joint meeting of Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will review Indivior’s NDA for RBP-6000 ​

* ‍FDA will consider advisory committee recommendation and will make final decision​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below